











434Rotigotine in Hemodialysis-Associated Restless Legs
Syndrome: A Randomized Controlled Trial
Yves Dauvilliers, MD, PhD,1 Heike Benes, MD,2,3 Markku Partinen, MD, PhD,4
Virpi Rauta, MD, PhD,5 Daniel Rifkin, MD,6 Elisabeth Dohin, MD,7
Nadine Goldammer, PhD,8 Erwin Schollmayer, MD, PhD,8 Hanna Schröder, DiplStat,8
and John W. Winkelman, MD, PhD9
Background: Restless legs syndrome (RLS) has been associated with insomnia, decreased quality of life,
and increased morbidity and mortality in end-stage renal disease. This randomized controlled trial investigated
effects of rotigotine in patients with RLS and end-stage renal disease.
Study Design: Double-blind placebo-controlled study.
Setting & Participants: Adults with moderate to severe RLS (International RLS Study Group Rating Scale
[IRLS] $ 15) and Periodic Limb Movement Index (PLMI) $ 15 who were receiving thrice-weekly hemodialysis
enrolled from sites in the United States and Europe.
Intervention: Following randomization and titration (#21 1 3 days) to optimal-dose rotigotine (1-3 mg/24 h)
or placebo, patients entered a 2-week maintenance period. Polysomnography was performed at baseline and
the end of maintenance.
Outcomes & Measurements: Primary efficacy outcome: reduction in PLMI, assessed by ratio of PLMI at
end of maintenance to baseline. Secondary/other outcomes (P values exploratory) included mean changes
from baseline in PLMI, IRLS, and Clinical Global Impression item 1 (CGI-1 [severity of illness]) score.
Results: 30 patients were randomly assigned (rotigotine, 20; placebo, 10); 25 (15; 10) completed the study
with evaluable data. Mean (SD) PLMI ratio (end of maintenance to baseline) was 0.76 0.4 for rotigotine and
1.36 0.7 for placebo (analysis of covariance treatment ratio, 0.44; 95% CI, 0.22 to 0.88; P5 0.02). Numerical
improvements were observed with rotigotine versus placebo in IRLS and CGI-1 (least squares mean treatment
differences of26.08 [95% CI,212.18 to 0.02; P 5 0.05] and20.81 [95% CI,21.94 to 0.33; P 5 0.2]). 10 of 15
rotigotine and 2 of 10 placebo patients were CGI-1 responders ($50% improvement). Hemodialysis did not
affect unconjugated rotigotine concentrations. The most common adverse events ($2 patients) were
nausea (rotigotine, 4 [20%]; placebo, 0); vomiting (3 [15%]; 0); diarrhea (1 [5%]; 2 [20%]); headache
(2 [10%]; 0); dyspnea (2 [10%]; 0); and hypertension (2 [10%]; 0).
Limitations: Small sample size and short duration.
Conclusions: Rotigotine improved periodic limb movements and RLS symptoms in the short term
among ESRD patients requiring hemodialysis in a small-scale study. No dose adjustments are necessary for
hemodialysis patients.
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(ESRD); randomized controlled trial (RCT).About 12% to 25% of patients with end-stage renaldisease (ESRD) are affected by the neurologic
disorder restless legs syndrome (RLS).1-3 Patients with
RLS have a bothersome urge to move their limbs,
particularly their legs, often associated with dyses-
thesias. Symptoms occur during times of rest, are
relieved by movement, and worsen in the evening and1SleepDisordersCenter,Department ofNeurology,Gui-
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riginally published online February 2, 2016.at night. Periodic limb movements (PLM) during sleep
(assessed by polysomnography) are present in 85% to
95% of patients with RLS.4 Such PLM are often
associated with microarousals in those with RLS and
thus contribute to sleep disruption. Most assessments
of RLS severity rely on subjective ratings of a patient’s
sensory symptoms. Quantification of PLM provides anTrial registration: www.ClinicalTrials.gov; study number:
NCT01537042.
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Rotigotine in Restless Legs Syndrome and ESRDobjective severity measure of the motor component of
this disorder. In patients with ESRD, the presence of
RLS has been associated with insomnia, decreased
quality of life, and increased morbidity andmortality.5-7
Symptoms of RLS may occur during dialysis ses-
sions and are independently associated with premature
discontinuation of dialysis.8
Treatment for RLS is targeted at easing symptoms
and improving sleep quality and quantity. Non-
pharmacologic treatment (eg, exercise training)9-11 or
correction of iron deficiency, common in ESRD, may
be appropriate therapy for those having mild or
infrequent symptoms. However, pharmacologic treat-
ment is often necessary for patients with more severe
disease. Monotherapy with either a nonergot dopa-
mine receptor agonist or an a2d calcium channel
ligand (only approved in the United States) is currently
recommended as the first-line treatment for patients
with primary RLS.12 In addition, levodopa is used in
certain European countries, including Germany.
However, few studies have investigated the efficacy of
these pharmacologic agents in patients with RLS and
comorbid ESRD.13-15
Rotigotine is a nonergot dopamine receptor agonist
administered by a transdermal patch, which provides
continuous drug delivery with stable plasma levels
over 24 hours.16 The efficacy of rotigotine trans-
dermal patch in moderate to severe primary RLS has
been demonstrated in two 6-month double-blind
studies that assessed symptom severity by subjective
rating scales17,18 and in a 4-week double-blind poly-
somnography study that used the PLM Index (PLMI;
PLM per hour in bed) as the primary outcome
measure.19 The current study was a randomized
controlled trial to investigate the efficacy of rotigotine
on PLM, sleep, RLS symptoms, and quality of life in
patients with RLS and ESRD requiring hemodialysis.Figure 1. Patient disposition.
aPatients who were rescreened
could have more than 1 reason for
screening failure. bThree patients
discontinued during the titration
period. cFull analysis set (FAS):
all randomly assigned patients
who had at least 1 patch applied
during the treatment period and
who had evaluable polysomno-
graphy data at baseline and end
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Patients
The RENALYS trial was a double-blind, randomized, placebo-
controlled, 2-arm, parallel-group polysomnography study con-
ducted in the United States and Europe. Adult patients (aged
between $18 and #85 years) with ESRD requiring hemodialysis
(regular dialysis schedule of 3 times weekly for at least 3 months)
were eligible to participate if they had a diagnosis of RLS based
on the International RLS Study Group (IRLSSG) criteria20
(RLS-diagnostic index score $ 11 points21), moderate to severe
RLS symptoms (IRLSSG Rating Scale [IRLS] score $ 15),22
Clinical Global Impression item 1 (CGI-1 [severity of illness]
score $ 4),23 and PLMI $ 15 PLM/h in bed (assessed by baseline
polysomnography). Additional criteria included body mass index
of 18 to #40 kg/m2, hemoglobin concentration $ 8 g/dL
($4.97 mmol/L), and ferritin concentration $ 100 ng/mL at
screening (visit 1). Patients were excluded if they had previous
treatment with rotigotine, symptomatic orthostatic hypotension, or
clinically relevant cardiovascular, venous, or arterial peripheral
diseases. Additional exclusion criteria included narcolepsy or
other disorders of central hypersomnia, clinically relevant poly-
neuropathy or varicosis, or additional clinically relevant concom-
itant diseases. Treatment with dopamine agonists within the 14
days prior to baseline (visit 2) or with levodopa, neuroleptics, or
selected other central nervous system–active medications within 7
days prior to baseline was prohibited. Patients who had previously
received dopaminergic therapy were required to have had an initial
favorable response. Additional patient eligibility criteria are given
in Item S1 (provided as online supplementary material). The study
was performed in accordance with Good Clinical Practice guide-
lines and the Declaration of Helsinki. The protocol was reviewed
by a national, regional, or independent ethics committee or insti-
tutional review board (Item S1), and all patients provided informed
consent.
Study Design
Following assessment of eligibility criteria (visit 1) and washout
of any prohibited medications, patients were randomly assigned
2:1 to rotigotine or placebo at baseline (visit 2). Randomization
was carried out by an interactive web response system (ICON
Clinical Research L.P.), with strata defined by region (European
























Male sex 13 (65) 7 (70)
Age, y 57.2 6 12.6 50.7 6 16.3
Age category
.18-,65 y 15 (75) 8 (80)
$65 y 5 (25) 2 (20)
BMI, kg/m2 30.4 6 4.3 28.96 6.2
Race
White 13 (65) 4 (40)
Black 6 (30) 2 (20)
Other/mixed 0 (0) 1 (10)
Missing dataa 1 (5) 3 (30)
Region
United States 12 (60) 6 (60)
European Union 8 (40) 4 (40)
Dialysis 3 times per week 20 (100) 10 (100)
Dialysis vintage,b y 3.7 (0-19) 2.5 (0-22)
Time since first RLS
symptoms, y
3.0 (1-13) 5.0 (0-9)
Time since first RLS
diagnosis, y
1.0 (0-9) 0.1 (0-5)
Prior RLS therapy 12 (60) 2 (20)
Gabapentin 4 (20) 0 (0)
Levodopa/dopamine
agonistsb
5 (25) 1 (10)
Pregabalin 2 (10) 1 (10)
Psycholepticsc 3 (15) 0 (0)
SBP
During day, mm Hg 140.96 24.4 141.06 9.5
During night, mm Hg 137.66 27.0 144.86 15.2
DBP
During day, mm Hg 79.1 6 12.8 83.06 7.4
During night, mm Hg 76.5 6 15.6 82.4 6 11.6
Hemoglobin, g/Ld 121.56 15.7 120.16 13.7
Ferritin, pmol/Ld 1,613.56 952.2 1,711.86 701.2
Apnea and Hypopnea Indexe
#15 15 (75) 7 (70)
.15 5 (25) 3 (30)
.30 5 (25) 0 (0)
Note: Values for categorical variables are given as number
(percentage); values for continuous variables, mean 6 standard
deviation or median (range).
Abbreviations: BMI, body mass index; DBP, diastolic blood
pressure; RLS, restless legs syndrome; SBP, systolic blood
pressure.
aData were not collected for patients in France.
bCategory includes levodopa preparations, pramipexole, and
ropinirole.
cCategory includes clonazepam, meprobamate, and
temazepam.
dRotigotine, n 5 18; placebo, n 5 9.
eNumber of apneas or hypopneas per hour of sleep.
Dauvilliers et alby a transdermal patch; active and placebo patches were matched in
size and appearance, with rotigotine patches corresponding to doses
of 1, 2, and 3 mg/24 h. Doses were uptitrated weekly from 1 mg/24
h of rotigotine (or matching placebo) until the optimal or maximal
dose (3 mg/24 h) was reached (maximum titration period, 21 1 3436days). Following titration, patients entered the 2-week maintenance
period (visit 5), during which no further dose adjustments were
permitted. The end-of-maintenance visit (visit 6) was followed by a
taper period (up to 4 days) and a 30 (13)-day safety follow-up
period.
Polysomnography was performed on the 2 consecutive nights
prior to baseline (visit 2) and on the 2 consecutive nights prior to the
end of the maintenance period (visit 6). Study assessments were
scheduled so that the second night of polysomnography started the
day after the previous dialysis. Polysomnography was recorded for
up to 8 hours (eg, 11:00 PM-7:00 AM), following standard operating
procedures.24 Recordings from the second night were used for
analysis. Polysomnography recordings were transferred to a central
reader and scored by trained personnel according to the American
Academy of Sleep Medicine guidelines.25 PLM during sleep and
during wakefulness were evaluated in accordance with the World
Association of Sleep Medicine Standards26 and the specifications
of Walters et al.27 PLM were defined as a series of 4 or more
consecutive leg movements of 0.5 to 10 seconds in duration, with
an intermovement interval of 5 to 90 seconds.25
Blood samples were collected at the start and end of the
maintenance period for measurement of plasma unconjugated and
total rotigotine. In addition, 24-hour blood pressure was recorded
at baseline and end of maintenance by an ambulatory device
(Spacelabs Healthcare Model 90207). These recordings took place
24 hours prior to the scheduled dialysis session. Blood pressure
was recorded every 20 minutes during the daytime (6:00 AM-10:00
PM) and once per hour during the night (10:00 PM-6:00 AM). Mean
day- and night-time blood pressures were calculated as the mean
of all available values recorded during the respective times.
Outcome Measures
The primary outcome was reduction in PLMI, assessed by the
PLMI ratio (calculated as PLMI at the end of maintenance/PLMI at
baseline). The PLMI ratio was used to account for potential high
variability in the PLMI. Secondary outcomes were mean changes
from baseline in PLMI, selected polysomnography measures (PLM
During SleepWith Arousal Index [PLM during sleep with arousals/
hour total sleep time (TST)] and sleep efficiency), and subjective
rating scales (IRLS sum score, CGI-1, RLS 6-item questionnaire
[RLS-6], RLS quality-of-life questionnaire [RLS-QoL28], and
36-Item Short FormHealth Survey [SF-36]). Changes from baseline
in PLM during Sleep Index (PLMSI; PLM during sleep/hour TST),
PLM During Wakefulness Index (PLM during awake epochs/hour
in awake epochs), and sleep parameters (TST, time in sleep stages,
wake after sleep onset, and sleep onset latency) were also assessed.
Rotigotine plasma concentrations and changes from baseline in
mean day- and night-time blood pressures were evaluated. Safety
outcomes included adverse events (AEs) and serious AEs.
Statistical Analyses
Sample size calculation was based on the primary efficacy
outcome and performed with nQuery Advisor, version 7.0
(Statistical Solutions Ltd.). It was estimated that 24 patients
(rotigotine, 16; placebo, 8) were required to provide 90% power
to demonstrate the superiority of rotigotine over placebo using a
1-sided test with a 0.025 significance level. Enrollment of 48
patients was planned in order to randomly assign 33 patients
(assumed dropout rate, w30% [eg, owing to screening failures])
and obtain data from 24 completers (assumed dropout rate,
w25%) for the primary analysis.
Efficacy analyses were performed for the full analysis set,
including all randomly assigned patients who had at least 1 patch
applied during the treatment period and who had evaluable poly-
somnography data at baseline and end of maintenance. Unless
otherwise specified, data were analyzed as observed with no
imputation of missing values. A post hoc analysis of IRLS, CGI-1,Am J Kidney Dis. 2016;68(3):434-443
Table 2. Polysomnographic Assessments in Full Analysis Set Population
Baseline Change From Baseline
LS Mean Treatment










PLMI: PLM/h in beda 81.8 6 37.5 85.3 6 67.3 223.76 38.7 10.3 6 21.0 234.75 (261.38 to 28.11); 0.01
PLMSI: PLM during
sleep/h TST
87.246 48.52 92.456 92.08 230.246 41.79 4.46 6 20.24 235.79 (263.34 to 28.23); 0.01
PLMSAI: PLM during sleep
with arousals/h TSTa
13.916 8.94 9.65 6 9.03 21.616 14.41 4.63 6 7.16 25.19 (215.36 to 4.98); 0.3
PLMWI: PLM during awake
epochs/h in awake
epochs
79.606 32.91 73.316 35.71 212.766 47.72 25.216 43.47 234.60 (272.41 to 3.22); 0.07
Sleep parameters
Sleep efficiency: sleep
time/time in bed [%]a
59.746 17.32 65.416 12.50 7.676 12.32 22.85 6 10.35 9.33 (0.37 to 18.28); 0.04
TST, min 284.236 80.18 312.556 60.53 39.306 58.76 213.056 48.66 46.77 (3.12 to 90.42); 0.04
Stage 1, min 97.306 32.24 95.656 33.14 29.746 40.99 28.15 6 34.27 38.60 (8.93 to 68.27); 0.01
Stage 2, min 89.806 38.22 100.156 40.28 3.806 19.82 21.26 6 29.76 1.82 (216.91 to 20.55); 0.8
Stage 3, min 50.506 24.65 67.206 21.98 9.106 29.24 21.60 6 27.71 11.43 (214.97 to 37.83); 0.4
REM, min 46.636 29.44 49.556 18.79 23.346 27.81 22.05 6 24.21 21.77 (224.82 to 21.27); 0.9
Sleep onset latency, min 59.206 57.80 44.606 38.65 218.936 83.87 12.756 34.45 218.32 (263.68 to 27.04); 0.4
Wake after sleep onset, min 167.636 75.87 142.606 69.54 228.806 52.11 25.95 6 51.46 219.96 (257.08 to 17.16); 0.3
Note: Unless otherwise indicated, values are given as mean 6 standard deviation. The full analysis set included all randomly
assigned patients who had at least 1 patch applied during the treatment period and who had evaluable polysomnography data at
baseline and end of maintenance.
Abbreviations: CI, confidence interval; LS, least squares; PLM, periodic limb movement; PLMI; PLM Index; PLMSAI, PLM During
Sleep With Arousal Index; PLMSI, PLM During Sleep Index; PLMWI, PLM During Wakefulness Index; REM, rapid eye movement;
TST, total sleep time.
aSecondary efficacy variable.
Rotigotine in Restless Legs Syndrome and ESRDRLS-6, and RLS-QoL data was performed for the safety set (all
randomly assigned patients who had at least 1 patch applied during
the treatment period) with last observation carried forward.
Analyses of safety were performed for the safety set.
For the primary outcome, analysis of covariance (ANCOVA)
was performed for the log-transformed PLMI ratio, with treatment
and region as factors and baseline as a covariate. Least squares
means (with 95% confidence intervals [CIs]) were calculated for
each treatment, and results were back-transformed for presentation.
Treatment effect was estimated on the basis of the ratio of the 2
treatments, as well as on the corresponding 95% CI. For all other
efficacy outcomes, summary statistics were provided and




This study was conducted in April 2012 to October
2013. Forty-nine patients were enrolled and 30 were
randomly assigned from 5 sites in the United States (18
patients) and 7 sites in Europe (12 patients [Finland,
France, Germany, and Italy]; Fig 1). Patients randomly
assigned to rotigotine had a shorter history of RLS
(median, 3 vs 5 years) but a longer time since RLS
diagnosis than those randomly assigned to placebo
(median, 1 vs 0.1 year; Table 1). All participants had
ESRD requiring hemodialysis. Concomitant diseases
reported by 10 or more patients were chronic kidneyAm J Kidney Dis. 2016;68(3):434-443disease (rotigotine: 14 [70%]; placebo: 8 [80%]), hy-
pertension (16 [80%]; 6 [60%]), gastroesophageal
reflux disease (7 [35%]; 5 [50%]), and hyper-
phosphatemia (7 [35%]; 3 [30%]; Table S1). Prior
RLS therapy was reported in 12 of 20 patients in the
rotigotine group and 2 of 10 patients in the placebo
group. Concomitant medications are shown in
Table S2. In total, 25 patients completed the study and
were included in efficacy analyses (full analysis set).
The 5 patients who discontinued prematurely were
all receiving rotigotine; 3 withdrew during titration,
and 2 withdrew during the maintenance period (Fig 1).
Of 16 rotigotine-treated patients with evaluable dosing
data at the start of maintenance, 9 received an optimal
daily dose of 3 mg/24 h, 3 received 2 mg/24 h, and 4
received 1 mg/24 h.
Efficacy (full analysis set)
Polysomnography Assessments
PLMI was comparable between the 2 treatment
groups at baseline, whereas assessments at the end of
maintenance showed a reduction in scores for patients
receiving rotigotine and an increase for those
receiving placebo (Table 2; Fig 2). The mean PLMI















































Placebo (n = 10) Rotigotine (n = 15)
A
B
Figure 2. Periodic Limb Movement Index (PLMI). (A) PLMI
ratio (end of maintenance to baseline) and (B) PLMI at baseline
and end of maintenance. Data for the full analysis set (all
randomly assigned patients who had at least 1 patch applied
during the treatment period, and who had evaluable polysomno-
graphy data at baseline and end of maintenance). Abbreviation:
SD, standard deviation.
Dauvilliers et alfor rotigotine compared with 1.36 0.7 for placebo
(treatment ratio, 0.44; 95% CI, 0.22-0.88; P 5 0.02).
Among patients receiving rotigotine, PLMI improved
from 81.8 6 37.5 at baseline to 58.16 37.6 at end
of maintenance (Table 2; Fig 2). The PLMSI was
reduced with rotigotine versus placebo (least squares
mean treatment difference, 235.79; 95% CI, 263.34
to 28.23; P 5 0.01), and sleep efficiency and TST
increased (least squares mean treatment differences of
9.33 [95% CI, 0.37-18.28; P 5 0.04] and 46.77 [95%
CI, 3.12-90.42; P 5 0.04]; Table 2). PLM During
Wakefulness Index, sleep onset latency, and wake
after sleep onset were reduced with rotigotine;
however, ANCOVAs did not indicate treatment
differences (Table 2).
Subjective Assessments
Greater numerical reductions in IRLS scores were
observed among rotigotine-treated patients who
completed the maintenance period (full analysis set)
than those receiving placebo (least squares mean
treatment difference, 26.08; 95% CI, 212.18 to 0.02;438P 5 0.05; Table 3; Fig 3A). Based on IRLS scores
at end of maintenance, 11 of 15 patients receiving
rotigotine treatment were classified as responders
($50% improvement), 8 of 15 qualified as remitters
(IRLS # 10), and 3 of 15 were symptom free
(IRLS 5 0). In the placebo group, 2 of 10 patients
were classified as IRLS responders, 1 of 10 qualified
as a remitter, and no patients were symptom free.
Mean CGI-1 scores numerically improved with roti-
gotine (least squares mean treatment
difference, 20.81; 95% CI, 21.94 to 0.33; P 5 0.2),
with 12 of 15 patients receiving rotigotine and 5 of 10
patients receiving placebo moving to a CGI-1 cate-
gory of mildly, borderline, or not at all ill (Fig 3B). At
end of maintenance, 10 of 15 patients receiving roti-
gotine and 2 of 10 patients receiving placebo were
classified as CGI-1 responders ($50% improvement
in score). RLS-6 scores were reduced in both treat-
ment groups, with greater numerical improvements
observed with rotigotine for all items other than item
5 (symptom severity during activities; Table 3). A
treatment difference in favor of rotigotine was
observed for RLS-6 item 6 (daytime sleepiness
tiredness). Rotigotine-treated patients had a slight
numerical improvement in RLS-QoL scores in com-
parison to those receiving placebo (Table 3). Analysis
of subjective RLS assessments for all treated patients
(safety set with last observation carried forward)
showed mean changes from baseline in IRLS, RLS-6,
and RLS-QoL scores that were comparable, though
systemically smaller, to those observed in the full
analysis set (Table S3).
Pharmacokinetics (Safety Set)
Plasma concentrations of dose-normalized uncon-
jugated rotigotine were similar at the start of mainte-
nance (geometric mean, 0.0505 [ng/mL]/mg; n 5 16)
and end of maintenance/withdrawal visit (0.0563
[ng/mL]/mg; n 5 15). Geometric mean values for
dose-normalized total rotigotine were also comparable
at both times (start of maintenance, 0.3561 [ng/mL]/
mg [n 5 16]; end of maintenance/withdrawal, 0.4000
[ng/mL]/mg [n 5 15]).
Blood Pressure (Safety Set and Full Analysis Set)
At baseline, mean systolic (SBP) and diastolic blood
pressure (DBP) values were comparable in both treat-
ment groups (Table 1). Among patients receiving roti-
gotine (safety set), slight mean reductions in daytime
(SBP,20.66 14.3 mm Hg;DBP,20.36 9.7 mm Hg)
and night-time (SBP, 21.26 12.1 mm Hg; DBP,
21.26 8.9 mm Hg) blood pressures were observed
at end of maintenance compared to baseline. In
comparison, increases from baseline in daytime
(SBP, 4.86 6.8 mm Hg; DBP, 2.46 3.7 mm Hg)
and night-time (SBP, 4.36 14.8 mm Hg; DBP,Am J Kidney Dis. 2016;68(3):434-443
Table 3. Subjective Assessments in the Full Analysis Set Population
Baseline Change From Baseline
LS Mean Treatment









IRLS 25.7 6 5.0 24.4 6 5.1 215.9 6 9.1 28.66 7.2 26.08 (212.18 to 0.02); 0.05
RLS-6
Item 1: Satisfaction with sleep 6.16 1.7 5.76 1.9 22.8 6 3.2 21.16 3.5 21.37 (23.91 to 1.17); 0.3
Item 2: Severity when falling asleep 6.66 2.1 5.86 2.7 24.4 6 2.9 22.86 2.9 21.08 (23.23 to 1.08); 0.3
Item 3: Severity during the night 6.26 2.0 5.96 1.9 24.7 6 3.1 23.26 2.6 21.25 (22.96 to 0.46); 0.1
Item 4: Severity when at rest 3.76 2.1 4.96 2.0 22.6 6 2.2 21.66 3.2 21.85 (23.86 to 0.17); 0.07
Item 5: Severity during activities 2.56 2.5 2.86 2.7 21.6 6 2.7 21.66 2.1 20.22 (21.54 to 1.11); 0.7
Item 6: Daytime sleepiness/tiredness 5.36 2.1 5.76 1.6 23.4 6 2.3 21.66 2.0 22.13 (23.67 to 20.60); 0.009
RLS-QoL 24.9 6 7.4 31.3 6 10.8 210.7 6 10.9 210.2 6 10.8 22.67 (212.42 to 7.08); 0.6
SF-36a
Mental Component Summary score 54.1 6 11.3 41.0 6 10.9 2.2 6 10.1 6.46 6.6 2.87 (24.67 to 10.42); 0.4
Physical Component Summary score 35.7 6 11.3 38.2 6 6.5 3.8 6 6.3 20.36 8.7 2.87 (22.85 to 8.59); 0.3
Note: Unless otherwise indicated, values are given as mean 6 standard deviation. The full analysis set included all randomly
assigned patients who had at least 1 patch applied during the treatment period, and who had evaluable polysomnography data at
baseline and end of maintenance.
Abbreviations: CI, confidence interval; IRLS, International Restless Legs Syndrome Rating Scale; LS, least squares; RLS-6, restless
legs syndrome 6-item questionnaire; RLS-QoL, restless legs syndrome quality-of-life questionnaire; SF-16, 36-Item Short Form Health
Survey.
aAn increase in score indicates an improvement; for all other outcomes, a reduction in score indicates an improvement.
Rotigotine in Restless Legs Syndrome and ESRD2.96 9.0 mm Hg) blood pressures were observed
with placebo. Post hoc analysis of night-time blood
pressure dipping was performed for the full analysis
set. The numbers of patients with a dip (.10% reduction
from day to night) in DBP (baseline, 3 of 15; end of
maintenance, 5 of 15) and SBP (baseline, 1 of 15; end of
maintenance, 4 of 15) increased with rotigotine. In the
placebo group, 2 of 10 patients were DBP dippers at
baseline and 1 of 10 was at end of maintenance. No pa-
tients receiving placebo were classified as SBP dippers.
Safety and Tolerability (Safety Set)
AEs were reported by 12 (60%) patients receiving
rotigotine and 5 (50%) patients receiving placebo
(Table 4). Two patients had hypertension of moder-
ate intensity while receiving rotigotine. Both patients
were receiving medications for this condition prior to
study start. One patient reported an application site
reaction (MedDRA [Medical Dictionary for Regu-
latory Activities] high-level term “application and
instillation site reactions”) of mild pruritus while
receiving 2 mg/24 h of rotigotine; no application site
reactions were reported for placebo. Serious AEs
were reported for 3 patients receiving rotigotine
(foot fracture [n 5 1]; anxiety, chest pain, and dys-
pnea [n 5 1]; and abdominal pain [n 5 1]) and 1
patient receiving placebo (gastrointestinal infection).
Two rotigotine-treated patients discontinued prema-
turely owing to AEs. One withdrew following a
confusional state; this AE occurred on day 9 of
rotigotine treatment (dose at onset: 1 mg/24 h) andAm J Kidney Dis. 2016;68(3):434-443was considered to be nonserious, moderate in
intensity, and related to study medication. Following
withdrawal of rotigotine treatment, the AE resolved
within 2 days. The other patient withdrew after
having a number of serious AEs (anxiety, chest pain,
and dyspnea). These AEs occurred on day 27 of
rotigotine treatment while the patient was receiving a
dose of 3 mg/24 h and were considered to be severe
in intensity and related to the study medication.
Following withdrawal of rotigotine, the chest pain
resolved in 3 days, anxiety resolved in 24 days, and
dyspnea resolved in 38 days.
DISCUSSION
Rotigotine transdermal patch significantly reduced
PLM, as assessed by the PLMI ratio. To our knowl-
edge, this is the first double-blind placebo-controlled
study to investigate rotigotine therapy for moderate
to severe RLS in patients with ESRD treated by
hemodialysis. Reduction in PLM with rotigotine was
supported by a reduction in PLMSI and accompanied
by improvements in certain sleep parameters.
Sleep problems are common in patients with ESRD,
particularly those with RLS, and contribute to reduced
quality of life.6 The severity of PLM during sleep has
been linked to increased risk for cardiovascular and
cerebrovascular disease29 and increased mortality in
this patient population.30,31 A higher frequency of
PLM has been reported in patients with uremic




































































Among the most extremely ill
















Figure 3. Subjective outcomes.
(A) International Restless LegsSyn-
drome Study Group Rating Scale
(IRLS) score and (B) Clinical Global
Impression item 1 severity scale
category at baseline and end of
maintenance. Data for the full anal-
ysis set (all randomly assigned pa-
tients who had at least 1 patch
applied during the treatment period
and who had evaluable polysom-
nography data at baseline and end
of maintenance). Abbreviation: SD,
standard deviation.
Dauvilliers et aldisorder.32,33 In the current study, patients had a
high frequency of PLM at baseline, with a mean
PLMI . 80/h. A PLMI . 50/h is generally consid-
ered to be severe. Although a significant improvement
in PLMI ratio was observed with rotigotine, the PLMI
for both treatment groups remained above the .50/h
cutoff at the end of the 2-week maintenance periodTable 4. Adverse Events Reported by 2 or More Patients
in the Safety Set
MedDRA Preferred Term Rotigotine (n 5 20) Placebo (n 5 10)
Any 12 (60) 5 (50)
Nausea 4 (20) 0 (0)
Vomiting 3 (15) 0 (0)
Diarrhea 1 (5) 2 (20)
Headache 2 (10) 0 (0)
Dyspnea 2 (10) 0 (0)
Hypertension 2 (10) 0 (0)
Note: Values are given as number (percentage).
Abbreviation: MedDRA, Medical Dictionary for Regulatory
Activities.
440(58.1 with rotigotine). Given the persisting high rates
of PLM at end of treatment, the clinical significance of
the observed reduction in PLMI with rotigotine is
unclear. In contrast, a longer study in patients with
idiopathic RLS (4-week maintenance period) showed
a reduction in PLMI from 50.9 to 8.1 with rotigotine.19
In addition to improving motor outcomes, rotigo-
tine treatment had beneficial effects on sleep, with
improvements versus placebo in sleep efficiency and
TST. Sensory symptoms of RLS also improved with
rotigotine, as indicated by numerical improvements
in subjective rating scale scores. The observed w16-
point reduction in IRLS score with rotigotine corre-
sponded to a shift from severe (IRLS, 21-30) to mild
symptoms (IRLS, 1-10).22 In comparison, patients
receiving placebo had an w9-point reduction in
IRLS score, with a shift from severe to moderate
(IRLS, 11-20) symptoms. These results were consis-
tent with those for the CGI-1, with the majority of
rotigotine-treated patients (and 50% of patients
receiving placebo) improving to a category of mildly,
borderline, or not at all ill. Numerical improvementsAm J Kidney Dis. 2016;68(3):434-443
Rotigotine in Restless Legs Syndrome and ESRDwere observed with rotigotine versus placebo in
severity of RLS during various periods of the night
and day, in addition to sleep satisfaction and daytime
tiredness, as assessed by the RLS-6. Quality-of-life
scores (RLS-QoL and SF-36) varied between treat-
ment groups at baseline, with a difference of w13
points in the SF-36 Mental Component Summary
score. Slight numerical improvements were observed
with rotigotine versus placebo. It should be noted that
this study was powered for assessment of the primary
outcome (PLMI ratio) only. All P values for sec-
ondary outcomes are exploratory and do not indicate
statistical significance.
Serum plasma concentrations of unconjugated and
total rotigotine were stable over the maintenance
phase, which indicates lack of accumulation, and
were similar to those seen in patients with RLS with
and without impaired renal function.16,34 This sup-
ports earlier demonstrations that rotigotine dose ad-
justments are not required for patients with reduced
kidney function, including those receiving hemodial-
ysis.34 Elimination of rotigotine from plasma is
comparable in healthy individuals and patients with
different stages of chronic kidney diseases, and roti-
gotine is not removed by the dialysis procedure.34 In
contrast, dose modifications are needed for prami-
pexole treatment.35
Analyses of ambulatory blood pressure–monitoring
data indicated slight numerical reductions in night-
time and daytime blood pressures and slight in-
creases in the number of night-time dippers with
rotigotine. Further studies with larger numbers of
patients and longer treatment durations are warranted
to fully investigate the effects of rotigotine on blood
pressure and night-time blood pressure–dipping sta-
tus. The AE profile of rotigotine was consistent with
that reported in other studies of patients with idio-
pathic RLS.17-19 In our small group of rotigotine-
treated patients, 2 AEs of hypertension were re-
ported; however, both cases were in patients with
preexisting antihypertensive treatment. Given that
dermatologic conditions are common among patients
with ESRD,36 it is notable that only 1 patient had a
skin reaction following patch application. However,
longer studies are needed to fully evaluate the toler-
ability of rotigotine in hemodialysis patients.
Limitations of the study were primarily its small
number of patients and short treatment duration.
Confirmatory studies are needed to fully assess the
efficacy of rotigotine in patients with ESRD treated
by hemodialysis. There were some potential imbal-
ances between treatment groups at baseline; for
example, the rotigotine group included a higher pro-
portion of pretreated patients. Patients in whom pre-
vious dopaminergic treatment had failed were
excluded from the study for ethical reasons. This mayAm J Kidney Dis. 2016;68(3):434-443have enriched the sample for likely responders.
Finally, because patients had to fulfill stringent
eligibility criteria, those enrolled may not be fully
representative of the wider hemodialysis population
with RLS.
In the current short-term small-scale study, rotigo-
tine was efficacious in improving PLM in patients
with ESRD treated by hemodialysis who had mod-
erate to severe RLS. Confirmatory trials are warranted
to determine whether rotigotine transdermal patch
may be of benefit in this patient population.ACKNOWLEDGEMENTS
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